# Inflamax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inflamax

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Latest round: Angel (Oct 20, 2023)
- Investors on record: 1

## About

Based in Guangzhou, China, and founded in 2022, Inflamax operates as a biopharmaceutical company that focuses on innovative drug for immune and inflammatory diseases. The founder, Micky D. Tortorella was a chief technology officer of the Guangzhou Biomedicine and Health Research Drug R&D Center of the Chinese Academy of Sciences. In January 2025, Inflamax closed a pre-series A funding led by new investor GCX Ventures.

Inflamax focuses on developing innovative drugs targeting the field of immune inflammation. The company has also launched four major FIC/BIC R&D pipelines in the field of immune inflammation. The products can be used to treat a variety of conditions including cancer, pain, neurological disorders, and osteoarthritis.

The company generates revenue by developing innovative drug for immune and inflammatory diseases.

The company will use the funds to support the first human clinical trial of MAX-001 in the treatment of advanced refractory solid tumors.

## Funding rounds

- Angel, Oct 20, 2023 — Redhill Capital

## Investors

- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Angel